Buprenorphine implant - Titan Pharmaceuticals

Drug Profile

Buprenorphine implant - Titan Pharmaceuticals

Alternative Names: Buprenorphine implant; Probuphine

Latest Information Update: 04 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Titan Pharmaceuticals
  • Developer Braeburn Pharmaceuticals; Knight Therapeutics; Titan Pharmaceuticals
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Opioid abuse
  • No development reported Pain

Most Recent Events

  • 31 May 2018 Titan Pharmaceuticals reacquires rights to commercialise and develop buprenorphine implant in the US and Canada from Braeburn Pharmaceuticals
  • 30 May 2018 Titan Pharmaceuticals terminates its licence with Braeburn Pharmaceuticals for buprenorphine implant in USA and Canada
  • 20 Apr 2018 Registered for Opioid abuse in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top